首页 > 最新文献

Cytopathology最新文献

英文 中文
Simple and rapid flow cytometry assay for the detection of malignant epithelial cells in body fluids. 用于检测体液中恶性上皮细胞的简单快速的流式细胞术检测方法。
IF 1.3 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-06-04 DOI: 10.1111/cyt.13408
Thulasi Raman Ramalingam, Sandeep Mani, Swetha Narla, Archana Lakshmanan, Anurekha Muthu, Harsha Rasheed Nk, Selvaraj Mohanraj, Ellapan Dharma Ramachandran, Annapurneswari Subramanyam, Lakshman Vaidhyanathan

Introduction: Morphology is routinely used for detecting malignant cells in body fluids, but it has limitations. Recently, flow cytometry (FCM) is used as an effective tool for studying non-haematological malignancies. The main objective of this study is to standardize a simple and rapid FCM test for the detection of malignant epithelial cells in body fluids.

Materials and methods: Body fluids that had been processed for cytology/cytology and FCM were enrolled in this prospective study. We developed a fluorescent-labelled, monoclonal antibody panel composed of cell surface markers for this FCM assay. We compared the results of cytology/cell block and FCM.

Results: A total of 121 fluid samples were studied. Comparing the diagnostic performance of cytology/cell block and FCM, 52 (43%) cases were positive and 60 (49.5%) cases were negative for carcinoma cells by both techniques. Nine cases showed discordant results between the two techniques. Six cases were cytology+ but FCM- and three cases were FCM+ cytology-. Clustered Epithelial Cell Adhesion Molecule (EpCAM)-positive events with high scatter properties were definitive for positive diagnosis by FCM. We studied PD-L1 expression in 13 cases by FCM. Six cases were reported as false negative by this FCM assay due to hypocellularity and lack of EpCAM expression in malignant cells.

Conclusions: This FCM assay is simple, easier and cost-effective yielding sensitive results with no inter-observer variability. FCM would become a valuable tool to complement routine diagnostic cytology and reduces misdiagnosis.

简介形态学是检测体液中恶性细胞的常规方法,但有其局限性。最近,流式细胞术(FCM)被用作研究非血液学恶性肿瘤的有效工具。本研究的主要目的是将用于检测体液中恶性上皮细胞的简单快速的 FCM 检测标准化:本前瞻性研究选取了经过细胞学/细胞学和 FCM 处理的体液。我们开发了一种荧光标记的单克隆抗体面板,由细胞表面标记物组成,用于 FCM 检测。我们比较了细胞学/细胞阻断和 FCM 的结果:共研究了 121 份液体样本。比较细胞学/细胞块和 FCM 的诊断性能,两种技术的癌细胞检测结果均为阳性的病例有 52 例(43%),阴性的病例有 60 例(49.5%)。有 9 例病例两种技术的结果不一致。6 例细胞学+ 但 FCM-,3 例 FCM+ 细胞学-。上皮细胞粘附分子(EpCAM)阳性的聚集事件具有高散射特性,可确定 FCM 诊断为阳性。我们通过 FCM 研究了 13 个病例的 PD-L1 表达。有 6 例病例由于细胞功能减退和恶性细胞中缺乏 EpCAM 表达而被 FCM 检测为假阴性:结论:这种 FCM 检测方法简单、方便、成本效益高,结果灵敏,观察者之间无差异。FCM 将成为补充常规细胞学诊断的重要工具,并能减少误诊。
{"title":"Simple and rapid flow cytometry assay for the detection of malignant epithelial cells in body fluids.","authors":"Thulasi Raman Ramalingam, Sandeep Mani, Swetha Narla, Archana Lakshmanan, Anurekha Muthu, Harsha Rasheed Nk, Selvaraj Mohanraj, Ellapan Dharma Ramachandran, Annapurneswari Subramanyam, Lakshman Vaidhyanathan","doi":"10.1111/cyt.13408","DOIUrl":"https://doi.org/10.1111/cyt.13408","url":null,"abstract":"<p><strong>Introduction: </strong>Morphology is routinely used for detecting malignant cells in body fluids, but it has limitations. Recently, flow cytometry (FCM) is used as an effective tool for studying non-haematological malignancies. The main objective of this study is to standardize a simple and rapid FCM test for the detection of malignant epithelial cells in body fluids.</p><p><strong>Materials and methods: </strong>Body fluids that had been processed for cytology/cytology and FCM were enrolled in this prospective study. We developed a fluorescent-labelled, monoclonal antibody panel composed of cell surface markers for this FCM assay. We compared the results of cytology/cell block and FCM.</p><p><strong>Results: </strong>A total of 121 fluid samples were studied. Comparing the diagnostic performance of cytology/cell block and FCM, 52 (43%) cases were positive and 60 (49.5%) cases were negative for carcinoma cells by both techniques. Nine cases showed discordant results between the two techniques. Six cases were cytology+ but FCM- and three cases were FCM+ cytology-. Clustered Epithelial Cell Adhesion Molecule (EpCAM)-positive events with high scatter properties were definitive for positive diagnosis by FCM. We studied PD-L1 expression in 13 cases by FCM. Six cases were reported as false negative by this FCM assay due to hypocellularity and lack of EpCAM expression in malignant cells.</p><p><strong>Conclusions: </strong>This FCM assay is simple, easier and cost-effective yielding sensitive results with no inter-observer variability. FCM would become a valuable tool to complement routine diagnostic cytology and reduces misdiagnosis.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141263608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in diagnostic liquid-based cytology 液基细胞学诊断技术的进展。
IF 1.2 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-06-04 DOI: 10.1111/cyt.13405
Hideyuki Abe, Akihiko Kawahara, Jun Akiba, Rin Yamaguchi

Liquid-based cytology (LBC) has changed the landscape of gynaecological cytology. A growing demand exists for LBC in diagnostic cytology, particularly for ancillary testing, such as immunocytochemistry and molecular testing. Ancillary testing solely based on conventional preparation (CP) methods remains challenging. Recently, the increased demand for specialist testing and minimally invasive techniques, such as endoscopic ultrasonography fine-needle aspiration, to obtain cellular samples has led to an increasing demand for ancillary testing on cytology LBC supernatant, slides and cell block (CB). This facilitates the diagnosis and prognosis in cytology samples enabling personalized treatment. An understanding of the history and future prospects of LBC is crucial for its application in routine diagnostics by cytopathologists and cytotechnologists. In this review, we initiated an internet search using the keyword ‘liquid-based cytology’, and we conducted a literature review to discuss the usefulness of combined diagnosis of LBC and CP, immunocytochemistry and molecular testing and assessed the quality of nucleic acids in diagnostic LBC. High-quality and cell-rich diagnostic LBC surpassed the CP method alone in terms of reliability and versatility of ancillary testing in cytological diagnosis. Conclusively, diagnostic LBC lends itself to various new technologies and is expected to continue evolving with innovations in the future.

液基细胞学(LBC)改变了妇科细胞学的格局。细胞学诊断对液基细胞学的需求日益增长,尤其是在免疫细胞化学和分子检测等辅助检测方面。仅基于传统制备(CP)方法的辅助检测仍具有挑战性。近来,对专科检测和微创技术(如内窥镜超声细针穿刺术)获取细胞样本的需求增加,导致对细胞学 LBC 上清、切片和细胞块(CB)辅助检测的需求不断增加。这有助于细胞学样本的诊断和预后,从而实现个性化治疗。了解 LBC 的历史和未来前景对细胞病理学家和细胞技术专家将其应用于常规诊断至关重要。在本综述中,我们以 "液基细胞学 "为关键词进行了网络搜索,并进行了文献综述,讨论了 LBC 和 CP 联合诊断、免疫细胞化学和分子检测的实用性,并评估了诊断性 LBC 中核酸的质量。就细胞学诊断中辅助检测的可靠性和多功能性而言,高质量和细胞丰富的诊断性 LBC 超过了单纯的 CP 方法。最后,诊断性 LBC 适用于各种新技术,预计未来将继续发展创新。
{"title":"Advances in diagnostic liquid-based cytology","authors":"Hideyuki Abe,&nbsp;Akihiko Kawahara,&nbsp;Jun Akiba,&nbsp;Rin Yamaguchi","doi":"10.1111/cyt.13405","DOIUrl":"10.1111/cyt.13405","url":null,"abstract":"<p>Liquid-based cytology (LBC) has changed the landscape of gynaecological cytology. A growing demand exists for LBC in diagnostic cytology, particularly for ancillary testing, such as immunocytochemistry and molecular testing. Ancillary testing solely based on conventional preparation (CP) methods remains challenging. Recently, the increased demand for specialist testing and minimally invasive techniques, such as endoscopic ultrasonography fine-needle aspiration, to obtain cellular samples has led to an increasing demand for ancillary testing on cytology LBC supernatant, slides and cell block (CB). This facilitates the diagnosis and prognosis in cytology samples enabling personalized treatment. An understanding of the history and future prospects of LBC is crucial for its application in routine diagnostics by cytopathologists and cytotechnologists. In this review, we initiated an internet search using the keyword ‘liquid-based cytology’, and we conducted a literature review to discuss the usefulness of combined diagnosis of LBC and CP, immunocytochemistry and molecular testing and assessed the quality of nucleic acids in diagnostic LBC. High-quality and cell-rich diagnostic LBC surpassed the CP method alone in terms of reliability and versatility of ancillary testing in cytological diagnosis. Conclusively, diagnostic LBC lends itself to various new technologies and is expected to continue evolving with innovations in the future.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 6","pages":"682-694"},"PeriodicalIF":1.2,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141263569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 探索多组学液体活检测试在肺癌临床环境中的潜力。
IF 1.2 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-06-01 DOI: 10.1111/cyt.13396
Andrea Gottardo, Tancredi Didier Bazan Russo, Alessandro Perez, Marco Bono, Emilia Di Giovanni, Enrico Di Marco, Rita Siino, Carla Ferrante Bannera, Clarissa Mujacic, Maria Concetta Vitale, Silvia Contino, Giuliana Iannì, Giulia Busuito, Federica Iacono, Lorena Incorvaia, Giuseppe Badalamenti, Antonio Galvano, Antonio Russo, Viviana Bazan, Valerio Gristina

The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non-invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour-related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi-marker, multi-analyte and multi-source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues.

人工智能(AI)和多组学的变革性作用可以提高肺癌液体活检(LB)的诊断和预后能力。尽管取得了进步,但从组织活检到更复杂的非侵入性方法(如液体活检)的过渡一直受到生物标记物异质性和肿瘤相关分析物浓度低等挑战的阻碍。由深度学习算法支持的多组学的出现提供了一种解决方案,它允许同时分析多种生物液体中的各种分析物,为癌症诊断带来了范式转变。本综述通过多标记、多分析物和多来源方法,展示了人工智能和多组学如何识别与患者健康状况相关的、具有临床价值的生物标记物组合。然而,临床实施的道路充满挑战,包括研究的可重复性和缺乏方法标准化,因此需要迫切的解决方案来解决这些常见问题。
{"title":"Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer","authors":"Andrea Gottardo,&nbsp;Tancredi Didier Bazan Russo,&nbsp;Alessandro Perez,&nbsp;Marco Bono,&nbsp;Emilia Di Giovanni,&nbsp;Enrico Di Marco,&nbsp;Rita Siino,&nbsp;Carla Ferrante Bannera,&nbsp;Clarissa Mujacic,&nbsp;Maria Concetta Vitale,&nbsp;Silvia Contino,&nbsp;Giuliana Iannì,&nbsp;Giulia Busuito,&nbsp;Federica Iacono,&nbsp;Lorena Incorvaia,&nbsp;Giuseppe Badalamenti,&nbsp;Antonio Galvano,&nbsp;Antonio Russo,&nbsp;Viviana Bazan,&nbsp;Valerio Gristina","doi":"10.1111/cyt.13396","DOIUrl":"10.1111/cyt.13396","url":null,"abstract":"<p>The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non-invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour-related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi-marker, multi-analyte and multi-source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 6","pages":"664-670"},"PeriodicalIF":1.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141187237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid molecular profiling utilising minimal quantities of endobronchial ultrasound-guided aspirates for the detection of Epidermal Growth Factor Receptor, KRAS, ALK, ROS1, RET, NTRK and MET gene alterations from patients with non-small-cell lung carcinomas on the Biocartis Idylla™ platform 在 Biocartis Idylla™ 平台上,利用极少量的支气管内超声引导抽吸物进行快速分子谱分析,检测非小细胞肺癌患者的表皮生长因子受体、KRAS、ALK、ROS1、RET、NTRK 和 MET 基因改变。
IF 1.2 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-30 DOI: 10.1111/cyt.13406
Alexander Haragan, Robert Lee

Objectives

Comprehensive molecular analysis for patients with non-small-cell lung carcinoma (NSCLC) is essential for managing modern targeted therapies. This study sought to establish the feasibility of utilising real-time PCR to perform rapid and comprehensive profiling on minimal amounts of endobronchial ultrasound-guided (EBUS) aspirates as a fast, tissue-sparing route of predictive profiling.

Methods

A volume of 500 μL of EBUS aspirate and fixative from patients with NSCLC was decanted, and 80 μL (<1% of total specimen received) was utilised for analysis. Biocartis Idylla™ cartridges for epidermal growth factor receptor (EGFR) mutations, KRAS mutations and a GeneFusion cartridge (ALK, ROS1, RET, NTRK1/2/3 rearrangements & MET 14 exon skipping) were analysed for each case to provide molecular data on the main clinically relevant targets as per UK guidelines.

Results

A total of 62 cases were included; all of which had successful DNA analysis (EGFR and KRAS cartridges). RNA analysis (GeneFusion cartridge) was successful for 42 of 51 (82%) with initial approach, with 11 of 11 (100%) achieving a successful result with modified protocol. In all, 23 KRAS mutations (37%), 5 EGFR mutations (8%) and 1 ROS fusion (2%) were identified. Average time from specimen receipt to molecular read-out was 5 h.

Conclusion

Real-time PCR utilising the Idylla™ platform is rapid, utilises minimal amounts of tissue and provides accurate results. We propose this is a useful ancillary method to utilise alongside next-generation sequencing (NGS) in cases of urgent clinical requirement or EBUS aspirates with inadequate quantities of tissue for NGS.

目标:对非小细胞肺癌(NSCLC)患者进行全面的分子分析对于管理现代靶向疗法至关重要。本研究试图确定利用实时 PCR 对极少量的支气管内超声引导(EBUS)吸出物进行快速、全面分析的可行性,以此作为一种快速、不损伤组织的预测性分析途径:方法:从 NSCLC 患者的 EBUS 吸出液和固定液中倾析出 500 μL 和 80 μL (结果:共纳入 62 个病例;所有病例均成功进行了 DNA 分析(表皮生长因子受体和 KRAS 试剂盒)。采用初始方法时,51 例中有 42 例(82%)成功进行了 RNA 分析(GeneFusion 试剂盒),采用修改方案时,11 例中有 11 例(100%)取得了成功。总共鉴定出 23 例 KRAS 突变(37%)、5 例 EGFR 突变(8%)和 1 例 ROS 融合(2%)。从标本接收到分子读出的平均时间为 5 小时:结论:利用 Idylla™ 平台进行实时 PCR 分析非常快速,只需使用极少量的组织,并能提供准确的结果。我们认为这是一种有用的辅助方法,可与下一代测序(NGS)一起用于临床急需或 EBUS 抽吸组织量不足以进行 NGS 的病例。
{"title":"Rapid molecular profiling utilising minimal quantities of endobronchial ultrasound-guided aspirates for the detection of Epidermal Growth Factor Receptor, KRAS, ALK, ROS1, RET, NTRK and MET gene alterations from patients with non-small-cell lung carcinomas on the Biocartis Idylla™ platform","authors":"Alexander Haragan,&nbsp;Robert Lee","doi":"10.1111/cyt.13406","DOIUrl":"10.1111/cyt.13406","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Comprehensive molecular analysis for patients with non-small-cell lung carcinoma (NSCLC) is essential for managing modern targeted therapies. This study sought to establish the feasibility of utilising real-time PCR to perform rapid and comprehensive profiling on minimal amounts of endobronchial ultrasound-guided (EBUS) aspirates as a fast, tissue-sparing route of predictive profiling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A volume of 500 μL of EBUS aspirate and fixative from patients with NSCLC was decanted, and 80 μL (&lt;1% of total specimen received) was utilised for analysis. Biocartis Idylla™ cartridges for epidermal growth factor receptor (EGFR) mutations, KRAS mutations and a GeneFusion cartridge (ALK, ROS1, RET, NTRK1/2/3 rearrangements &amp; MET 14 exon skipping) were analysed for each case to provide molecular data on the main clinically relevant targets as per UK guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 62 cases were included; all of which had successful DNA analysis (EGFR and KRAS cartridges). RNA analysis (GeneFusion cartridge) was successful for 42 of 51 (82%) with initial approach, with 11 of 11 (100%) achieving a successful result with modified protocol. In all, 23 <i>KRAS</i> mutations (37%), 5 <i>EGFR</i> mutations (8%) and 1 ROS fusion (2%) were identified. Average time from specimen receipt to molecular read-out was 5 h.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Real-time PCR utilising the Idylla™ platform is rapid, utilises minimal amounts of tissue and provides accurate results. We propose this is a useful ancillary method to utilise alongside next-generation sequencing (NGS) in cases of urgent clinical requirement or EBUS aspirates with inadequate quantities of tissue for NGS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 5","pages":"648-653"},"PeriodicalIF":1.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear long diameter as a new criterion to distinguish high-grade urothelial carcinoma cells from benign reactive cells 核长直径是区分高级别尿路上皮癌细胞和良性反应细胞的新标准。
IF 1.2 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-28 DOI: 10.1111/cyt.13397
Kazuma Sakumo, Juri Tamura, Akihiro Nakamura, Takuhisa Nukaya, Tadashi Sofue, Reiji Haba, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki

Objective

Recently, the nuclear area has attracted attention as a morphological parameter to differentiate high-grade urothelial carcinoma (HGUC) cells from benign reactive cells. The nuclear long diameter (NLD) strongly correlates with the nuclear area and is easy to subjectively estimate. Therefore, this study examined the usefulness of the NLD-to-neutrophil diameter ratio for detecting HGUC cells in urine cytology.

Methods

This study included 29, 26 and 18 patients with HGUC, glomerular disease and urolithiasis respectively. An image analysis system was used to measure the NLD of HGUC and benign reactive cells (reactive renal tubular cells and reactive urothelial cells) and the neutrophil diameter that appeared in the voided urine in these cases. The NLD index was calculated using the NLD-to-neutrophil diameter ratio. We subsequently compared HGUC and benign reactive cells with respect to NLD and NLD indices. In addition, the HGUC cell group and benign reactive cell group were compared by selecting the five cells with the largest NLD and NLD index on each slide.

Results

The NLD and NLD indices of HGUC cells were significantly higher than those of benign reactive cells in all cells and in the five cells with the largest NLD and NLD indices. The cut-off value of the NLD index for detecting HGUC cells was 1.25 in all cells and 1.80 in the five cells with the largest NLD index.

Conclusions

The NLD index is a useful parameter that can be introduced into routine microscopic examinations to differentiate HGUC cells from benign reactive cells.

目的:最近,核面积作为区分高级别尿路上皮癌细胞(HGUC)和良性反应细胞的形态学参数引起了关注。核长直径(NLD)与核面积密切相关,且易于主观估计。因此,本研究探讨了 NLD 与中性粒细胞直径比值在尿液细胞学中检测 HGUC 细胞的实用性:本研究分别纳入了 29、26 和 18 名 HGUC、肾小球疾病和尿路结石患者。使用图像分析系统测量这些病例的 HGUC 和良性反应性细胞(反应性肾小管细胞和反应性尿路上皮细胞)的 NLD 以及排出的尿液中出现的中性粒细胞直径。NLD 指数是通过 NLD 与中性粒细胞直径之比计算得出的。随后,我们比较了 HGUC 和良性反应性细胞的 NLD 和 NLD 指数。此外,我们还在每张玻片上选取了五个NLD和NLD指数最大的细胞,对HGUC细胞组和良性反应性细胞组进行了比较:结果:HGUC 细胞的 NLD 和 NLD 指数在所有细胞和 NLD 和 NLD 指数最大的 5 个细胞中均明显高于良性反应性细胞。检测 HGUC 细胞的 NLD 指数临界值在所有细胞中为 1.25,在 NLD 指数最大的 5 个细胞中为 1.80:结论:NLD指数是一个有用的参数,可用于常规显微镜检查,以区分HGUC细胞和良性反应性细胞。
{"title":"Nuclear long diameter as a new criterion to distinguish high-grade urothelial carcinoma cells from benign reactive cells","authors":"Kazuma Sakumo,&nbsp;Juri Tamura,&nbsp;Akihiro Nakamura,&nbsp;Takuhisa Nukaya,&nbsp;Tadashi Sofue,&nbsp;Reiji Haba,&nbsp;Tomoo Itoh,&nbsp;Shingo Kamoshida,&nbsp;Hiroyuki Ohsaki","doi":"10.1111/cyt.13397","DOIUrl":"10.1111/cyt.13397","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Recently, the nuclear area has attracted attention as a morphological parameter to differentiate high-grade urothelial carcinoma (HGUC) cells from benign reactive cells. The nuclear long diameter (NLD) strongly correlates with the nuclear area and is easy to subjectively estimate. Therefore, this study examined the usefulness of the NLD-to-neutrophil diameter ratio for detecting HGUC cells in urine cytology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included 29, 26 and 18 patients with HGUC, glomerular disease and urolithiasis respectively. An image analysis system was used to measure the NLD of HGUC and benign reactive cells (reactive renal tubular cells and reactive urothelial cells) and the neutrophil diameter that appeared in the voided urine in these cases. The NLD index was calculated using the NLD-to-neutrophil diameter ratio. We subsequently compared HGUC and benign reactive cells with respect to NLD and NLD indices. In addition, the HGUC cell group and benign reactive cell group were compared by selecting the five cells with the largest NLD and NLD index on each slide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The NLD and NLD indices of HGUC cells were significantly higher than those of benign reactive cells in all cells and in the five cells with the largest NLD and NLD indices. The cut-off value of the NLD index for detecting HGUC cells was 1.25 in all cells and 1.80 in the five cells with the largest NLD index.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The NLD index is a useful parameter that can be introduced into routine microscopic examinations to differentiate HGUC cells from benign reactive cells.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 5","pages":"642-647"},"PeriodicalIF":1.2,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141163044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative cytology of CNS tumours: Challenges associated with an evolving landscape 中枢神经系统肿瘤的术中细胞学:与不断变化的形势相关的挑战。
IF 1.2 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-24 DOI: 10.1111/cyt.13395
José A. Jiménez Heffernan, Isabel Esteban-Rodríguez, Philippe Vielh

Despite recent changes in the classification of tumours of the central nervous system (WHO 5th edition, 2021), the basis for intraoperative diagnosis of these tumours remains basically the same. This Special Issue is intended to be an atlas showing in an orderly fashion, and following the recent WHO classification, the cytologic features of known and new tumours and the challenges they pose for the pathologist.

尽管中枢神经系统肿瘤的分类最近发生了变化(世卫组织第 5 版,2021 年),但这些肿瘤的术中诊断基础基本保持不变。本特刊旨在按照最新的世卫组织分类,有序地展示已知和新发肿瘤的细胞学特征,以及它们给病理学家带来的挑战。
{"title":"Intraoperative cytology of CNS tumours: Challenges associated with an evolving landscape","authors":"José A. Jiménez Heffernan,&nbsp;Isabel Esteban-Rodríguez,&nbsp;Philippe Vielh","doi":"10.1111/cyt.13395","DOIUrl":"10.1111/cyt.13395","url":null,"abstract":"<p>Despite recent changes in the classification of tumours of the central nervous system (WHO 5th edition, 2021), the basis for intraoperative diagnosis of these tumours remains basically the same. This Special Issue is intended to be an atlas showing in an orderly fashion, and following the recent WHO classification, the cytologic features of known and new tumours and the challenges they pose for the pathologist.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 5","pages":"532-533"},"PeriodicalIF":1.2,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastases to the parotid glands: An institutional experience 腮腺转移:机构经验。
IF 1.3 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-16 DOI: 10.1111/cyt.13387
Lea Calo, Tiziana Alboni, Carmine Bruno, Federica Policardo, Angela Feraco, Pietro Tralongo, Federica Vegni, Antonio Mulè, Francesca Brigato, Giorgia Rossi, Francesco Bussu, Liron Pantanowitz, Jacopo Galli, Esther Diana Rossi

Background

Metastatic lesions to the salivary gland are rare and mostly affect the parotids. Metastases represent 8% of all malignant lesions of the parotid gland. Around 80% originate from squamous cell carcinomas (SCC) of the head and neck region. Fine needle aspiration (FNA) plays a crucial role in distinguishing primary salivary gland lesions from metastases. Herein we describe our series of metastases to the parotid glands.

Materials and Methods

We analysed 630 parotid gland FNAs over a decade including conventional and liquid-based cytology specimens. Ancillary techniques such as immunocytochemistry (ICC) were conducted on cell blocks.

Results

Eighty (12.4%) cases were malignant lesions, of which 53 (63.75%) were metastases including 24% melanoma, 22.6% SCC, 19% renal carcinomas, 7.5% breast carcinomas, 11.3% lung, 9% intestinal and 1.8% testicular, malignant solitary fibrous tumour and Merkel cell carcinoma. The 53 cases, classified according to the Milan system for salivary cytopathology, belonged to 5 Suspicious for malignancy (SFM) and 48 malignant (M) categories. Forty had a known history of primary malignancy (75.4%), while 13 were suspicious to be a metastatic localisation (24.5%), distributed as 5SFM (2SCC and 3Melanoma) and 8 M. A combination of clinical history, cytomorphology and ICC identified 100% of them.

Conclusions

Fine needle aspiration plays a central role in the diagnostic workup of patients with metastatic lesions to their parotid glands, thereby defining the correct management. Diagnostic accuracy may be enhanced by applying ICC. Although melanoma and SCC are the most common histological types, several other malignancies may also metastasize to the parotid glands and should be kept into consideration.

背景:唾液腺转移性病变非常罕见,主要影响腮腺。转移瘤占腮腺所有恶性病变的 8%。其中约80%源自头颈部的鳞状细胞癌(SCC)。细针穿刺术(FNA)在区分原发性涎腺病变和转移瘤方面起着至关重要的作用。在此,我们对腮腺转移瘤进行了系列描述:我们分析了十年间 630 例腮腺 FNA,包括传统细胞学标本和液基细胞学标本。对细胞块进行了免疫细胞化学(ICC)等辅助技术处理:80例(12.4%)为恶性病变,其中53例(63.75%)为转移瘤,包括24%的黑色素瘤、22.6%的SCC、19%的肾癌、7.5%的乳腺癌、11.3%的肺癌、9%的肠癌和1.8%的睾丸癌、恶性单发纤维瘤和梅克尔细胞癌。根据米兰唾液细胞病理学系统对 53 例病例进行了分类,其中 5 例为可疑恶性(SFM),48 例为恶性(M)。其中 40 例有已知的原发性恶性肿瘤病史(75.4%),13 例可疑为转移灶(24.5%),分布为 5SFM (2SCC 和 3Melanoma)和 8 M。结合临床病史、细胞形态学和 ICC,100% 的患者都被确定为转移灶:结论:细针穿刺术在腮腺转移性病变患者的诊断工作中发挥着核心作用,从而确定了正确的治疗方法。应用 ICC 可以提高诊断的准确性。虽然黑色素瘤和鳞状细胞癌是最常见的组织学类型,但其他几种恶性肿瘤也可能转移到腮腺,因此也应考虑在内。
{"title":"Metastases to the parotid glands: An institutional experience","authors":"Lea Calo,&nbsp;Tiziana Alboni,&nbsp;Carmine Bruno,&nbsp;Federica Policardo,&nbsp;Angela Feraco,&nbsp;Pietro Tralongo,&nbsp;Federica Vegni,&nbsp;Antonio Mulè,&nbsp;Francesca Brigato,&nbsp;Giorgia Rossi,&nbsp;Francesco Bussu,&nbsp;Liron Pantanowitz,&nbsp;Jacopo Galli,&nbsp;Esther Diana Rossi","doi":"10.1111/cyt.13387","DOIUrl":"10.1111/cyt.13387","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metastatic lesions to the salivary gland are rare and mostly affect the parotids. Metastases represent 8% of all malignant lesions of the parotid gland. Around 80% originate from squamous cell carcinomas (SCC) of the head and neck region. Fine needle aspiration (FNA) plays a crucial role in distinguishing primary salivary gland lesions from metastases. Herein we describe our series of metastases to the parotid glands.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We analysed 630 parotid gland FNAs over a decade including conventional and liquid-based cytology specimens. Ancillary techniques such as immunocytochemistry (ICC) were conducted on cell blocks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighty (12.4%) cases were malignant lesions, of which 53 (63.75%) were metastases including 24% melanoma, 22.6% SCC, 19% renal carcinomas, 7.5% breast carcinomas, 11.3% lung, 9% intestinal and 1.8% testicular, malignant solitary fibrous tumour and Merkel cell carcinoma. The 53 cases, classified according to the Milan system for salivary cytopathology, belonged to 5 Suspicious for malignancy (SFM) and 48 malignant (M) categories. Forty had a known history of primary malignancy (75.4%), while 13 were suspicious to be a metastatic localisation (24.5%), distributed as 5SFM (2SCC and 3Melanoma) and 8 M. A combination of clinical history, cytomorphology and ICC identified 100% of them.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Fine needle aspiration plays a central role in the diagnostic workup of patients with metastatic lesions to their parotid glands, thereby defining the correct management. Diagnostic accuracy may be enhanced by applying ICC. Although melanoma and SCC are the most common histological types, several other malignancies may also metastasize to the parotid glands and should be kept into consideration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 4","pages":"488-496"},"PeriodicalIF":1.3,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cyt.13387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristic morphology and immunohistochemical patterns of clear cell papillary renal cell tumours may be observed in renal cell carcinomas, a critical pitfall in renal biopsy cytopathology 在肾细胞癌中可能会观察到透明细胞乳头状肾细胞瘤的特征性形态和免疫组化模式,这是肾脏活检细胞病理学中的一个关键陷阱。
IF 1.3 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-15 DOI: 10.1111/cyt.13384
Xiaoqi Lin

Background

Clear cell papillary renal cell tumour (CCPRCT) was renamed from previous clear cell papillary renal cell carcinoma (CCPRCC) in the latest WHO Classification of Tumours. It is essential to differentiate RCC from CCPRCT in renal mass biopsies (RMB).

Design

RMB cases with subsequent resections were reviewed. The pathology reports and pertinent clinical information were recorded.

Results

Fifteen cases displaying either CCPRCT morphology (20% diffuse, 67% focal) or immunohistochemical patterns (cup-like CA9: 20% diffuse, 47% focal; CK7: 33% diffuse, 40% focal) were identified. One case was positive for TFE3. TSC mutation was identified in one case. Both cases exhibited both CCPRCT morphology and immunohistochemical patterns for CA9 and CK7, with focal high-grade nuclei. RMB diagnoses were as follows: 6 (40%) as CCRCC, 2 (13%) as CCPRCT, 2 (13%) as CCRCC versus CCPRCT, 2 (13%) as CCRCC versus PRCC, 1 (7%) as RCC with TSC mutation versus CCPRCT, 1 (7%) as TFE3-rearranged RCC versus PRCC, and 1 (7%) as cyst with low-grade atypia. 71% of patients underwent nephrectomy, 21% received systemic treatment for stage 4 RCCs, and 7% with ablation for small renal mass (1.6 cm) with low-grade CCRCC.

Conclusions

Our study highlights that morphologic and immunochemical features of CCPRCT may be present in RCCs, including RCC-TFE3 expression and TSC-associated RCC, a critical pitfall to misdiagnose aggressive RCC as indolent CCPRCT and result in undertreatment. Careful examination of morphology and immunostains for CA9, CK7, and TFE3, as well as molecular tests, is crucial for distinguishing aggressive RCC from indolent CCPRCT.

背景:在最新的世界卫生组织肿瘤分类中,透明细胞乳头状肾细胞瘤(CCPRCT)由以前的透明细胞乳头状肾细胞癌(CCPRCC)更名而来。在肾肿块活检(RMB)中区分 RCC 和 CCPRCT 至关重要:设计:对随后进行切除的肾肿块活检病例进行回顾性研究。结果:15 例病例显示为 CCPRCT 或 RCC:结果:15 例病例显示出 CCPRCT 形态(20% 弥漫性,67% 局灶性)或免疫组化模式(杯状 CA9:20% 弥漫性,47% 局灶性;CK7:33% 弥漫性,40% 局灶性)。一个病例的TFE3呈阳性。一个病例发现了 TSC 基因突变。两例病例均表现出CCPRCT形态和CA9及CK7免疫组化模式,并伴有灶性高级别核。人民币诊断结果如下:6例(40%)为CCRCC,2例(13%)为CCPRCT,2例(13%)为CCRCC与CCPRCT的对比,2例(13%)为CCRCC与PRC的对比,1例(7%)为TSC突变的RCC与CCPRCT的对比,1例(7%)为TFE3重排的RCC与PRC的对比,1例(7%)为低度不典型性囊肿。71%的患者接受了肾切除术,21%的患者接受了针对4期RCC的全身治疗,7%的患者因肾脏肿块较小(1.6厘米)伴有低级别CCRCC而接受了消融治疗:我们的研究强调,CCPRCT的形态学和免疫化学特征可能存在于RCC中,包括RCC-TFE3表达和TSC相关RCC,这是将侵袭性RCC误诊为轻度CCPRCT并导致治疗不当的一个关键隐患。仔细检查形态学、CA9、CK7 和 TFE3 的免疫印迹以及分子检测对于区分侵袭性 RCC 和轻度 CCPRCT 至关重要。
{"title":"Characteristic morphology and immunohistochemical patterns of clear cell papillary renal cell tumours may be observed in renal cell carcinomas, a critical pitfall in renal biopsy cytopathology","authors":"Xiaoqi Lin","doi":"10.1111/cyt.13384","DOIUrl":"10.1111/cyt.13384","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clear cell papillary renal cell tumour (CCPRCT) was renamed from previous clear cell papillary renal cell carcinoma (CCPRCC) in the latest WHO Classification of Tumours. It is essential to differentiate RCC from CCPRCT in renal mass biopsies (RMB).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>RMB cases with subsequent resections were reviewed. The pathology reports and pertinent clinical information were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifteen cases displaying either CCPRCT morphology (20% diffuse, 67% focal) or immunohistochemical patterns (cup-like CA9: 20% diffuse, 47% focal; CK7: 33% diffuse, 40% focal) were identified. One case was positive for TFE3. TSC mutation was identified in one case. Both cases exhibited both CCPRCT morphology and immunohistochemical patterns for CA9 and CK7, with focal high-grade nuclei. RMB diagnoses were as follows: 6 (40%) as CCRCC, 2 (13%) as CCPRCT, 2 (13%) as CCRCC versus CCPRCT, 2 (13%) as CCRCC versus PRCC, 1 (7%) as RCC with TSC mutation versus CCPRCT, 1 (7%) as TFE3-rearranged RCC versus PRCC, and 1 (7%) as cyst with low-grade atypia. 71% of patients underwent nephrectomy, 21% received systemic treatment for stage 4 RCCs, and 7% with ablation for small renal mass (1.6 cm) with low-grade CCRCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study highlights that morphologic and immunochemical features of CCPRCT may be present in RCCs, including RCC-TFE3 expression and TSC-associated RCC, a critical pitfall to misdiagnose aggressive RCC as indolent CCPRCT and result in undertreatment. Careful examination of morphology and immunostains for CA9, CK7, and TFE3, as well as molecular tests, is crucial for distinguishing aggressive RCC from indolent CCPRCT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 4","pages":"481-487"},"PeriodicalIF":1.3,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cyt.13384","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How many more slides to go until we fully adopt digital cytology? 在我们全面采用数字细胞学之前,还需要多少张幻灯片?
IF 1.3 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-12 DOI: 10.1111/cyt.13388
Catarina Eloy, Andrey Bychkov, Filippo Fraggetta, Jordi Temprana-Salvador, Liron Pantanowitz, Philippe Vielh

Two-liner/synopsis: The digital cytology hub (DCH) has been established under the umbrella of the Cytopathology journal. DCH will help bring about the crucial changes needed to make digital cytology the way of practicing cytology in our laboratories.

两行字/简介:数字细胞学中心(DCH)已在《细胞病理学》杂志的框架下成立。数字细胞学中心将帮助实现所需的关键变革,使数字细胞学成为我们实验室细胞学实践的方式。
{"title":"How many more slides to go until we fully adopt digital cytology?","authors":"Catarina Eloy,&nbsp;Andrey Bychkov,&nbsp;Filippo Fraggetta,&nbsp;Jordi Temprana-Salvador,&nbsp;Liron Pantanowitz,&nbsp;Philippe Vielh","doi":"10.1111/cyt.13388","DOIUrl":"10.1111/cyt.13388","url":null,"abstract":"<p><b>Two-liner/synopsis</b>: The digital cytology hub (DCH) has been established under the umbrella of the Cytopathology journal. DCH will help bring about the crucial changes needed to make digital cytology the way of practicing cytology in our laboratories.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 4","pages":"442-443"},"PeriodicalIF":1.3,"publicationDate":"2024-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tall-columnar glandular cells in SurePath™ liquid-based cytology Pap sample: Learning from mimics/pitfalls SurePath™ 液基细胞学巴氏涂片样本中的高柱状腺细胞:从模仿/陷阱中学习。
IF 1.3 4区 医学 Q4 CELL BIOLOGY Pub Date : 2024-05-07 DOI: 10.1111/cyt.13385
Nalini Gupta, Vanita Jain, Radhika Srinivasan, Tulika Singh

We offer a comprehensive depiction of the cytomorphological characteristics of lobular endocervical glandular hyperplasia (LEGH) as observed in SurePath™ liquid-based cytology (LBC), subsequently confirmed on cone biopsy.

Lobular endocervical glandular hyperplasia (LEGH), a precursor to gastric-type adenocarcinoma (GAE) of the endocervix, is rare and reports of it in cervical cytology are scarce. We provide a thorough description of the cytomorphological features of LEGH observed in SurePath™ liquid-based cytology (LBC), later confirmed by cone biopsy. To the best of our knowledge, this is the first report documenting cytology of LEGH in LBC of a Pap sample.

我们全面描述了 SurePath™ 液基细胞学检查(LBC)中观察到的宫颈小叶内腺体增生(LEGH)的细胞形态学特征,这些特征随后在锥体活检中得到证实。宫颈内膜腺体小叶增生(LEGH)是宫颈内膜胃型腺癌(GAE)的前驱病变,非常罕见,在宫颈细胞学中的报道也很少。我们对在 SurePath™ 液基细胞学(LBC)中观察到的 LEGH 的细胞形态学特征进行了详尽的描述,随后通过锥切活检进行了确认。据我们所知,这是第一份在巴氏涂片样本的液基细胞学检查中发现 LEGH 的报告。
{"title":"Tall-columnar glandular cells in SurePath™ liquid-based cytology Pap sample: Learning from mimics/pitfalls","authors":"Nalini Gupta,&nbsp;Vanita Jain,&nbsp;Radhika Srinivasan,&nbsp;Tulika Singh","doi":"10.1111/cyt.13385","DOIUrl":"10.1111/cyt.13385","url":null,"abstract":"<p>We offer a comprehensive depiction of the cytomorphological characteristics of lobular endocervical glandular hyperplasia (LEGH) as observed in SurePath™ liquid-based cytology (LBC), subsequently confirmed on cone biopsy.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p><p>Lobular endocervical glandular hyperplasia (LEGH), a precursor to gastric-type adenocarcinoma (GAE) of the endocervix, is rare and reports of it in cervical cytology are scarce. We provide a thorough description of the cytomorphological features of LEGH observed in SurePath™ liquid-based cytology (LBC), later confirmed by cone biopsy. To the best of our knowledge, this is the first report documenting cytology of LEGH in LBC of a Pap sample.</p>","PeriodicalId":55187,"journal":{"name":"Cytopathology","volume":"35 4","pages":"510-514"},"PeriodicalIF":1.3,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cytopathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1